The prognostic value of quantitative analysis of CCL5 and collagen IV in luminal B (HER2–) subtype breast cancer by quantum-dot-based molecular imaging

The prognostic value of quantitative analysis of CCL5 and collagen IV in luminal B (HER2–) subtype breast cancer by quantum-dot-based molecular imaging

Yong-yun Zhu,1 Chuang Chen,2 Juan-Juan Li,2 Sheng-Rong Sun2 1Department of Thyroid and Breast Surgery, Wuhu Second People’s Hospital, Wuhu, Anhui 24100, People’s Republic of China; 2Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 43006...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zhu YY, Chen C, Li JJ, Sun SR
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
Quantum dot
Luminal B (HER2-)
Chemokine (C-C motif) ligand 5
Collagen IV
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/21b4fcb840a546bb94b8080d9352e120
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:21b4fcb840a546bb94b8080d9352e120
record_format dspace
spelling oai:doaj.org-article:21b4fcb840a546bb94b8080d9352e1202021-12-02T03:34:47ZThe prognostic value of quantitative analysis of CCL5 and collagen IV in luminal B (HER2–) subtype breast cancer by quantum-dot-based molecular imaging1178-2013https://doaj.org/article/21b4fcb840a546bb94b8080d9352e1202018-06-01T00:00:00Zhttps://www.dovepress.com/the-prognostic-value-of-quantitative-analysis-of-ccl5-and-collagen-iv--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Yong-yun Zhu,1 Chuang Chen,2 Juan-Juan Li,2 Sheng-Rong Sun2 1Department of Thyroid and Breast Surgery, Wuhu Second People’s Hospital, Wuhu, Anhui 24100, People’s Republic of China; 2Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, People’s Republic of China Objective: Breast cancer is the most common malignancy and one of the main causes of death in women. Luminal B (HER2-) breast cancer subtype has been proposed since the 2011 St Gallon consensus. The hormone receptor status in this type of breast cancer is positive; thus, endocrine therapy was performed in all cases, but the treatment was not satisfactory, and a significant number of cases received very little benefit from chemotherapy. Furthermore, there is no effective treatment target for this subtype. Luminal B (HER2-) breast cancer subtype has been proposed since the 2011 St Gallon consensus. Therefore, the study of the key molecules in the microenvironment of breast cancer can help to reveal the biological characteristics. Patients and methods: Luminal B (HER2-) breast cancer is a subtype with higher heterogeneity and poorer prognosis than luminal A. It is known that the development of cancer cells is an active process, and this process needs microenvironment cytokines, including chemokine (C–C motif) ligand 5 (CCL5) and collagen IV. Therefore, CCL5 and collagen IV were imaged and detected by quantum dot, and the CCL5/collagen IV ratio was calculated to investigate the prognostic value of the CCL5/collagen IV ratio in luminal B (HER2-). Results: Quantitative determination showed a statistically significant negative correlation between CCL5 and collagen IV. The 5-year disease-free survival (5-DFS) of the high and low CCL5/collagen IV ratio subgroups was significantly different. The CCL5/collagen IV ratio had a greater prognostic value for 5-DFS. The CCL5/collagen IV ratio was an independent prognostic indicator. Conclusion: Our findings revealed the effective integration of tumor CCL5 and collagen IV, and a new method for predicting the prognosis of luminal B (HER2-) has been developed. Keywords: quantum dot, luminal B, HER2-, chemokine, C–C motif, ligand 5, collagen IVZhu YYChen CLi JJSun SRDove Medical PressarticleQuantum dotLuminal B (HER2-)Chemokine (C-C motif) ligand 5Collagen IVMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 3795-3803 (2018)
institution DOAJ
collection DOAJ
language EN
topic Quantum dot
Luminal B (HER2-)
Chemokine (C-C motif) ligand 5
Collagen IV
Medicine (General)
R5-920
spellingShingle Quantum dot
Luminal B (HER2-)
Chemokine (C-C motif) ligand 5
Collagen IV
Medicine (General)
R5-920
Zhu YY
Chen C
Li JJ
Sun SR
The prognostic value of quantitative analysis of CCL5 and collagen IV in luminal B (HER2–) subtype breast cancer by quantum-dot-based molecular imaging
description Yong-yun Zhu,1 Chuang Chen,2 Juan-Juan Li,2 Sheng-Rong Sun2 1Department of Thyroid and Breast Surgery, Wuhu Second People’s Hospital, Wuhu, Anhui 24100, People’s Republic of China; 2Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, People’s Republic of China Objective: Breast cancer is the most common malignancy and one of the main causes of death in women. Luminal B (HER2-) breast cancer subtype has been proposed since the 2011 St Gallon consensus. The hormone receptor status in this type of breast cancer is positive; thus, endocrine therapy was performed in all cases, but the treatment was not satisfactory, and a significant number of cases received very little benefit from chemotherapy. Furthermore, there is no effective treatment target for this subtype. Luminal B (HER2-) breast cancer subtype has been proposed since the 2011 St Gallon consensus. Therefore, the study of the key molecules in the microenvironment of breast cancer can help to reveal the biological characteristics. Patients and methods: Luminal B (HER2-) breast cancer is a subtype with higher heterogeneity and poorer prognosis than luminal A. It is known that the development of cancer cells is an active process, and this process needs microenvironment cytokines, including chemokine (C–C motif) ligand 5 (CCL5) and collagen IV. Therefore, CCL5 and collagen IV were imaged and detected by quantum dot, and the CCL5/collagen IV ratio was calculated to investigate the prognostic value of the CCL5/collagen IV ratio in luminal B (HER2-). Results: Quantitative determination showed a statistically significant negative correlation between CCL5 and collagen IV. The 5-year disease-free survival (5-DFS) of the high and low CCL5/collagen IV ratio subgroups was significantly different. The CCL5/collagen IV ratio had a greater prognostic value for 5-DFS. The CCL5/collagen IV ratio was an independent prognostic indicator. Conclusion: Our findings revealed the effective integration of tumor CCL5 and collagen IV, and a new method for predicting the prognosis of luminal B (HER2-) has been developed. Keywords: quantum dot, luminal B, HER2-, chemokine, C–C motif, ligand 5, collagen IV
format article
author Zhu YY
Chen C
Li JJ
Sun SR
author_facet Zhu YY
Chen C
Li JJ
Sun SR
author_sort Zhu YY
title The prognostic value of quantitative analysis of CCL5 and collagen IV in luminal B (HER2–) subtype breast cancer by quantum-dot-based molecular imaging
title_short The prognostic value of quantitative analysis of CCL5 and collagen IV in luminal B (HER2–) subtype breast cancer by quantum-dot-based molecular imaging
title_full The prognostic value of quantitative analysis of CCL5 and collagen IV in luminal B (HER2–) subtype breast cancer by quantum-dot-based molecular imaging
title_fullStr The prognostic value of quantitative analysis of CCL5 and collagen IV in luminal B (HER2–) subtype breast cancer by quantum-dot-based molecular imaging
title_full_unstemmed The prognostic value of quantitative analysis of CCL5 and collagen IV in luminal B (HER2–) subtype breast cancer by quantum-dot-based molecular imaging
title_sort prognostic value of quantitative analysis of ccl5 and collagen iv in luminal b (her2–) subtype breast cancer by quantum-dot-based molecular imaging
publisher Dove Medical Press
publishDate 2018
url https://doaj.org/article/21b4fcb840a546bb94b8080d9352e120
work_keys_str_mv AT zhuyy theprognosticvalueofquantitativeanalysisofccl5andcollagenivinluminalbher2ndashsubtypebreastcancerbyquantumdotbasedmolecularimaging
AT chenc theprognosticvalueofquantitativeanalysisofccl5andcollagenivinluminalbher2ndashsubtypebreastcancerbyquantumdotbasedmolecularimaging
AT lijj theprognosticvalueofquantitativeanalysisofccl5andcollagenivinluminalbher2ndashsubtypebreastcancerbyquantumdotbasedmolecularimaging
AT sunsr theprognosticvalueofquantitativeanalysisofccl5andcollagenivinluminalbher2ndashsubtypebreastcancerbyquantumdotbasedmolecularimaging
AT zhuyy prognosticvalueofquantitativeanalysisofccl5andcollagenivinluminalbher2ndashsubtypebreastcancerbyquantumdotbasedmolecularimaging
AT chenc prognosticvalueofquantitativeanalysisofccl5andcollagenivinluminalbher2ndashsubtypebreastcancerbyquantumdotbasedmolecularimaging
AT lijj prognosticvalueofquantitativeanalysisofccl5andcollagenivinluminalbher2ndashsubtypebreastcancerbyquantumdotbasedmolecularimaging
AT sunsr prognosticvalueofquantitativeanalysisofccl5andcollagenivinluminalbher2ndashsubtypebreastcancerbyquantumdotbasedmolecularimaging
_version_ 1718401718477127680

Ejemplares similares